New marker of angiogenesis CD105 (endoglin): Diagnostic, prognostic and therapeutic role

Radiology and Oncology

Volumn 39, Issue 4, 2005, Pages

  Legan, Mateja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Angiogenesis factor; Neoplasms blood supply; Neovascularisation, pathologic; Prognosis

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; ENDOGLIN; VON WILLEBRAND FACTOR;

CORRELATION ANALYSIS; HUMAN; MICROVASCULATURE; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVIEW; TISSUE SECTION; TUMOR VASCULARIZATION; VASCULARIZATION;

EID: 31544433391     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Folkman J, Watson K, Ingiber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
3. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
4. Weidner N. The importance of tumor angiogenesis: the evidence continues to grow. Am J Clin Pathol 2004; 122(5): 675-7.
5. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6): 401-10.
6. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49(23): 6449-65.
7. Khan AW, Dhillon AP, Hutchins R, Abraham A, Shah SR, Snooks S, et al. Prognostic significance of intratumoural microvessel density (IMD) in resected pancreatic and ampullary cancers to standard histopathological variables and survival. Eu J Surg Oncol 2002; 28(6): 637-44.
8. Mineo TC, Ambrogi V, Baldi A, Rabitti P, Bollero P, Vincenzi B, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 2004; 57(6): 591-7.
9. Uzzan B, Nicolas P, Cucherat M, Perrret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004; 64: 2941-55.
10. Middleton J, Americh L, Gayon R, Julien D, Mansat M, Mansat P, et al. A comparative stuady of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146. J Pathol 2005; 206(3): 260-8.
11. Wang JM, Kumar S, Pye D, Haboubi N, al-Nakib L. Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 1994; 86(5): 386-8.
12. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43(9): 752-7.
13. Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M, et al. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 2002; 131(1 Suppl): S109-13.
14. Yu JX, Zhang Xt, Liao YQ, Zhang QY, Chen H, Lin M, et al. Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol 2003; 9(12): 2866-9.
15. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer 2000; 36(5): 675-81.
16. Gougos A, Letarte M. Indentification of human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988; 141(6): 1925-33.
17. Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, et al. Endoglin: An accessory component of the TGF-beta-binding receptor - complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001; 188(1): 1-7.
18. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105) : a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003; 22(42): 6557-63.
19. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med 2004; 2: 18.
20. Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 2005; 46(5): 481-9.
21. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, et al. Defective angiogenesis in mice lacking endoglin. Science 1999; 284(5419): 1534-7.
22. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, et al. Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000; 217(1): 42-53.
23. Mc Allister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary hemorrhagic teleangiectasia type 1. Nat Genet 1994; 8: 345-51.
24. Qu R, Silver MM, Letarte M. Distribution of endoglin in early human development reveals high levels on endocardial cushion tissue mesenchyme during valve formation. Cell Tissue Res 1998; 292(2): 333-43.
25. Vincent EB, Runyan RB, Weeks DL. Production of the transforming growth factor-beta binding protein endoglin is regulated during chick heart development. Dev Dyn 1998; 213(3): 237-47.
26. Torsney E, Charlton R, Parums D, Collis M, Arthur HM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 2002; 51(9): 464-70.
27. Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 2000; 153(2): 323-35.
28. Botella LM, Sanz-Rodriguez F, Sanchez-Elsner T, Langa C, Ramirez JR, Vary C, et al. Lumican is down-regulated in cells expressing endoglin. Evidence for an inverse correlationship between Endoglin and Lumican expression. Matrix Biol 2004; 22(7): 561-72.
29. Brouillard P, Vikkula M. Vascular malformations: localized defects in vascular morphogenesis. Clin Genet 2003; 63(5): 340-51.
30. Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, McAsey ME. Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol 2000; 96(2): 224-8.
31. Saad RS, Liu Yl, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004; 17(2): 197-203.
32. Akagi K, Ikeda Y, Sumiyoshi Y, Kimura Y, Kinoshita J, Miyazaki M, et al. Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 2002; 131(1 Suppl): S109-13.
33. Martone T, Rosso P, Albera R, Migliaretti G, Fraire F, Pignataro L, et al. Prognostic relevance of CD105+ microvessel density in HNSCC patient outcome. Oral Oncol 2005; 41(2): 147-55.
34. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7(11): 3410-5.
35. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999; 59(4): 856-61.
36. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003; 88(9): 1424-31.
37. Delahunt B, Bethwaite PB, Thornton A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol 1997; 80(3): 401-4.
38. Ho JW, Poon RT, Sun CK, Xue WC, Fan ST. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol 2005; 11(2): 176-81.
39. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999; 5(2): 371-82.
40. Fonsatti E, Jekunen AP, Kairemo KJA, Coral S, Snellman M, Nicotra MR, et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000; 6(5): 2037-43.
41. Savontaus MJ, Sauter BV, Huang TG, Woo SL. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther 2002; 9(14): 972-9.
42. She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in supression of growth of human endothelial cells. Int J Cancer 2004; 108(2): 251-7.
43. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001; 61(21): 7846-54.
44. Li C, Guo B, Wilson PB, Stewart A, Bryne G, Bundred N, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 2000; 89(2): 122-6.
45. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and supressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001; 7(3): 524-32.